Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07452016 · ClinicalTrials.gov registry record · NA
AI-guided Prediction and Treatment of Cardiac Arrest
A NA study, sponsored by MetroHealth Medical Center.
- Not yet
- Registry status
- NA
- Development phase
- 68
- Enrollment target
NCT07452016: Clinical Trial NA study, sponsored by MetroHealth Medical Center.
NCT07452016 is a NA study that has not yet begun recruiting, run by MetroHealth Medical Center. The registered enrollment target is 68 participants, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (95% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT07452016, a NA study, has not yet begun recruiting, sponsored by MetroHealth Medical Center.
- NOT YET RECRUITING
- Registry status
- NA
- Development phase
- 68 participants
- Enrollment target
Study Summary
Sudden cardiac arrest is a major health problem, and most people don't survive. One big reason is that even if resuscitation is successful, people commonly have recurrent cardiac arrests (rearrest). Right now, it is not possible to accurately predict a rearrest or prevent it. The investigators have developed a machine learning device that uses the heart tracing (ECG) to predict when and why a rearrest occurs. The investigators plan to test if it will accurately and effectively help EMS providers predict rearrest and provide timely treatment to increase survival after cardiac arrest. To determine if this machine learning device will work in the real world, the investigators need to find out if there are barriers to using it, and whether EMS providers will think it is useful and will help them improve the care of patients who have a cardiac arrest. The investigators will first test the device in live simulated cardiac arrest scenarios to see if the providers can use it and if they find the device potentially valuable in taking care of patients. In a second study, the investigators will test how accurate the device is in predicting if a cardiac arrest will happen again in patients who have just been brought back to life after a cardiac arrest. EMS providers will attach the device, but it will only work in the background. EMS will take care of patients as they normally would, without using or knowing what the device says. To see if the device is accurate at predicting another cardiac arrest, the investigators will analyze the results offline, and compare what the device says to what actually happens to the patient. By comparing what the device predicts to what actually happens, the investigators can see how well it predicts another cardiac arrest and estimate how it might improve treatment of patients.
Primary Outcome
Mean score on a 20-item post-simulation survey adapted from the Consolidated Framework for Implementation Research (CFIR). Each item is rated on a 5-point Likert scale from 1 (strongly disagree) to 5 (strongly agree). The composite score is calculated as the mean of all items (range 1-5), with higher scores indicating greater perceived implementation acceptability.
Interventions
- DEVICE Machine learning-guided cardiac arrest prediction device
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 68 participants |
| Start Date | 2026-08 |
| Est. Completion | 2029-06 |
| Phase | NA |
What is known before NCT07452016 opens enrollment
NCT07452016 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 68 participants, a relatively small participant target, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (95% lower).
The record links to 0 conditions, and to 1 intervention - of which Machine learning-guided cardiac arrest prediction device is the first listed.
NCT07452016 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT07452016 about?
NCT07452016 is a clinical study titled "AI-guided Prediction and Treatment of Cardiac Arrest". Sudden cardiac arrest is a major health problem, and most people don't survive. One big reason is that even if resuscitation is successful, people commonly have recurrent cardiac arrests (rearrest). Right now, it is not possible to accurately predict a rearrest or prevent it. The investigators have ...
What is the current status of trial NCT07452016?
This trial is currently not yet recruiting. It is a NA study. The enrollment target is 68 participants. The study started on 2026-08. Estimated completion is 2029-06.
What interventions are being tested in trial NCT07452016?
The interventions under investigation include: Machine learning-guided cardiac arrest prediction device (DEVICE).
Who is sponsoring clinical trial NCT07452016?
This trial is sponsored by MetroHealth Medical Center, which has 76 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT07452016's enrollment target sits among peer trials
68 1133rd of 2000 higher than 862 of 2,000 other NA trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other NA trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02044497 · 68 participants · Phase 4
Population Pharmacokinetics and Pharmacogenomics of Oral Oxycodone in Pediatric Surgical Patients
- NCT03779854 · 68 participants · Phase 2
Naive T Cell Depletion for Preventing Chronic Graft-versus-Host Disease in Children and Young Adults With Blood Cancers Undergoing Donor Stem Cell Transplant
- NCT03821246 · 68 participants · Phase 2
Neoadjuvant Atezolizumab-Based Combination Therapy in Men With Localized Prostate Cancer Prior to Radical Prostatectomy
- NCT04115514 · 68 participants · Phase 2
Treatment of ARDS With Instilled T3
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia